The approval of medicines called second-generation antipsychotics has allowed bipolar I and other associated conditions to be treated. A person with bipolar I disorder can go through various mood ...

The approval of medicines called second-generation antipsychotics has allowed major depressive disorder (MDD) and other conditions linked to it to be treated. A person with MDD is usually prescribed ...

Some people experience weight gain during treatment with Vraylar. While exercise may be helpful, it’s crucial not to overheat or dehydrate. Taking Vraylar can affect your metabolism, such as ...

AbbVie’s antipsychotic Vraylar could get a major boost from a potential expansion into depression. But like some other late-stage contenders, the drug’s clinical results fell short of a home run.

Allergan's new launch Vraylar may have a chance in the crowded antipsychotic market, if it can shine at treating schizophrenia's “negative” symptoms, such as lack of emotion and loss of interest in ...

Many people with major depressive disorder don’t get enough relief from their symptoms despite antidepressant medication. To potentially rectify the problem, the U.S. Food and Drug Administration (FDA ...

Allergan plcAGN and Hungary-based partner Gedeon Richter Plc. have announced positive top-line results from the third pivotal study, evaluating the companies' schizophrenia drug Vraylar (cariprazine) ...

It’s not known whether Vraylar is safe to take while pregnant or breastfeeding. Certain factors, including the risks of not treating your condition during pregnancy, may determine whether you should ...

The FDA today approved Vraylar to treat schizophrenia and bipolar disorder in adults, according to a press release. Efficacy of Vraylar (cariprazine, Forest Laboratories) for schizophrenia was ...

The approval was based on data from 2 trials in adults who met DSM-IV-TR or DSM-5 criteria for MDD and had an inadequate response to 1 to 3 courses of prior antidepressant therapy. The Food and Drug ...

This listing is a new step towards more equitable access to mental illness medication in Canada. As up to 90% of Canadians with serious mental illness are unemployed 3, public plan coverage is ...